Literature DB >> 16082578

Percutaneous closure of perimembranous ventricular septal defects with the eccentric Amplatzer device: multicenter follow-up study.

J Masura1, W Gao, P Gavora, K Sun, A Q Zhou, S Jiang, L Ting-Liang, Y Wang.   

Abstract

Using an Amplatzer membranous eccentric occluder, 186 patients with an average weight of 43.5 kg (range 12.5-77) underwent attempted catheter closure of a perimembranous venricular septal defect (PMVSD). Their age ranged from 3 to 51 years, with the an average age being 15.9 years. The patients were divided into three groups according to morphology of PMVSD: 106 patients with single PMVSD, 63 patients with single PMVSD with aneurysmatic formation, and 17 patients with multiple VSD with aneurysmatic formation. Using angiography, PMVSDs were measured to be between 2.5 and 12 mm, with an average of 5.1 mm. In the third group of patients, we did not measure the size of PMVSD and a device was selected according to the size of entry to the aneurysm. The device was successfully implanted in all patients. The immediate closure rate was 90% in the first group, increasing to 100% at 1 month and remained at that level during follow-up. The immediate closure rate in the second group was 98% and remained the same during follow-up. The immediate closure rate in the third group was 89% and during 1 year of follow-up remained the same. There was no clinical evidence of hemolysis and no incidence of device embolization or bacterial endocarditis after implantation. Before the procedure, all patients showed normal electrocardiogram (ECG) or left ventricle enlargement. After the procedure (at least 3 months later) ECG showed left anterior hemiblock (LAH) in nine patients, complete right bundle branch block in eight patients, and incomplete right bundle branch block in seven patients. A complete heart block (CHB) developed in 2 patients after the procedure (1.07%). The first patient developed LAH immediately after closure and CHB within 24 hours, The heart rate was 28 beats per minute. After treatment with steroids and atropine, CHB changed to sinus rhythm with LAH within 2 months. One year later, the ECG revealed the same findings. The second patient developed CHB immediately after the procedure and was on temporary pacing for 1 week. After 1 month, the patient recovered to sinus rhythm and ECG showed LAH.

Entities:  

Mesh:

Year:  2005        PMID: 16082578     DOI: 10.1007/s00246-005-1003-7

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  12 in total

1.  Perforation of the right aortic valve cusp: complication of ventricular septal defect closure with a modified Rashkind umbrella.

Authors:  M Vogel; M L Rigby; D Shore
Journal:  Pediatr Cardiol       Date:  1996 Nov-Dec       Impact factor: 1.655

2.  Early ECG abnormalities associated with transcatheter closure of atrial septal defects using the Amplatzer septal occluder.

Authors:  S L Hill; C I Berul; H T Patel; J Rhodes; S E Supran; Q L Cao; Z M Hijazi
Journal:  J Interv Card Electrophysiol       Date:  2000-10       Impact factor: 1.900

3.  Transcatheter closure of congenital ventricular septal defects: experience with various devices.

Authors:  Ramesh Arora; Vijay Trehan; Ashish Kumar; G S Kalra; Madhuri Nigam
Journal:  J Interv Cardiol       Date:  2003-02       Impact factor: 2.279

4.  Catheter closure of atrial septal and ventricular septal defects using the Amplatzer devices.

Authors:  Ziyad M Hijazi
Journal:  Heart Lung Circ       Date:  2003       Impact factor: 2.975

5.  Catheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder: initial clinical experience.

Authors:  Ziyad M Hijazi; Fakhri Hakim; A Abu Haweleh; Awni Madani; Walid Tarawna; Aktham Hiari; Qi-Ling Cao
Journal:  Catheter Cardiovasc Interv       Date:  2002-08       Impact factor: 2.692

6.  Transcatheter closure of perimembranous ventricular septal defects with the Amplatzer asymmetric ventricular septal defect occluder: preliminary experience in children.

Authors:  B D Thanopoulos; G S Tsaousis; E Karanasios; N G Eleftherakis; C Paphitis
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

7.  Restrictive ventricular septal defect: how small is too small to close?

Authors:  C L Backer; R C Winters; V R Zales; H Takami; A J Muster; D W Benson; C Mavroudis
Journal:  Ann Thorac Surg       Date:  1993-11       Impact factor: 4.330

8.  Initial human experience with the Amplatzer perimembranous ventricular septal occluder device.

Authors:  John L Bass; G S Kalra; Ramesh Arora; Jozef Masura; Pavlo Gavora; Basil D Thanopoulos; William Torres; Horst Sievert; Mario Carminati; Gunther Fischer; Peter Ewert
Journal:  Catheter Cardiovasc Interv       Date:  2003-02       Impact factor: 2.692

9.  Primary transcatheter umbrella closure of perimembranous ventricular septal defect.

Authors:  M L Rigby; A N Redington
Journal:  Br Heart J       Date:  1994-10

10.  Occlusion of congenital ventricular septal defects by the buttoned device. "Buttoned device" Clinical Trials International Register.

Authors:  E B Sideris; K P Walsh; J L Haddad; C R Chen; S G Ren; H Kulkarni
Journal:  Heart       Date:  1997-03       Impact factor: 5.994

View more
  23 in total

Review 1.  Radiographic appearance of pediatric cardiovascular transcatheter devices.

Authors:  Ryan J Williams; Daniel S Levi; John W Moore; M Ines Boechat
Journal:  Pediatr Radiol       Date:  2006-08-05

2.  Transcatheter closure of perimembranous ventricular septal defect: is the risk of heart block too high a price?

Authors:  Ian D Sullivan
Journal:  Heart       Date:  2006-10-11       Impact factor: 5.994

3.  Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: shunt lesions.

Authors:  Candice K Silversides; Annie Dore; Nancy Poirier; Dylan Taylor; Louise Harris; Matthias Greutmann; Lee Benson; Helmut Baumgartner; David Celermajer; Judith Therrien
Journal:  Can J Cardiol       Date:  2010-03       Impact factor: 5.223

4.  Transcatheter closure of perimembranous ventricular septal defect.

Authors:  Anita Dumitrescu; Geoffrey K Lane; James L Wilkinson; T H Goh; Daniel J Penny; Andrew M Davis
Journal:  Heart       Date:  2007-07       Impact factor: 5.994

5.  Transcatheter closure of perimembranous ventricular septal defects (VSD) with VSD occluder: early and mid-term results.

Authors:  Yidong Wei; Xian Wang; Shouyan Zhang; Lei Hou; Yong Wang; Yawei Xu; Qi Sun; Huaibing Zhao
Journal:  Heart Vessels       Date:  2011-05-27       Impact factor: 2.037

6.  Retrograde closure of perimembranous ventricular septal defect using muscular ventricular septal occluder: a single-center experience of a novel technique.

Authors:  Kalyanasundaram Muthusamy
Journal:  Pediatr Cardiol       Date:  2014-08-20       Impact factor: 1.655

7.  Arrhythmias after transcatheter closure of perimembranous ventricular septal defects with a modified double-disk occluder: early and long-term results.

Authors:  Pan Li; Xian-xian Zhao; Xing Zheng; Yong-wen Qin
Journal:  Heart Vessels       Date:  2011-06-04       Impact factor: 2.037

8.  Interventional VSD-Closure with the Nit-Occlud® Lê VSD-Coil in 110 Patients: Early and Midterm Results of the EUREVECO-Registry.

Authors:  Nikolaus A Haas; Laura Kock; Harald Bertram; Regina Boekenkamp; Daniel De Wolf; Igor Ditkivskyy; Matthias W Freund; Marc Gewillig; Christoph M Happel; Ulrike Herberg; Edvard Karthasyan; Rainer Kozlik-Feldmann; Oliver Kretschmar; Yulia Kuzmenko; Ornella Milanesi; Goetz Mueller; Giacomo Pongiglione; Stephan Schubert; Gleb Tarusinov; Christoph Kampmann
Journal:  Pediatr Cardiol       Date:  2016-11-15       Impact factor: 1.655

9.  Perventricular closure of perimembranous ventricular septal defects using the concentric occluder device.

Authors:  Shunmin Wang; Zhongyun Zhuang; Haibo Zhang; Jinhao Zhen; Yanan Lu; Jinfen Liu; Zhiwei Xu
Journal:  Pediatr Cardiol       Date:  2013-11-07       Impact factor: 1.655

10.  New design of the Amplatzer membranous VSD occluder: a step forward?

Authors:  Kiran Mallula; Najma Patel; Zahid Amin
Journal:  Pediatr Cardiol       Date:  2013-02-02       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.